[Phoniatric studies in myasthenia gravis patients].
The authors have for the first time evaluated the basic parameters of the voice using computed voice analysis in patients with myasthenia gravis (MG). The aim of the study was to introduce an objective method suitable for the assessment of dysphonic symptoms, which predominate in bulbar, oculobulbar and generalized MG. Voice profile studies included the evaluation of the singing voice range, voice dynamics, maximum phonation time, and mean fundamental frequency and intensity during speech. The characteristic of the stroboscopic picture was also determined. Investigations were carried out before and after the intake of Mestinon, a reversible cholinesterase inhibitor, and healthy subjects were used as a control group. In MG, the voice range and dynamics are badly impaired, maximum phonation time is shortened, the mean fundamental frequency during speech is increased, while the intensity is decreased. Mestinon resulted in an improvement in all these parameters, however, they were still impaired in comparison to the control subjects. Most changes were found to be statistically significant. The authors emphasize the role of the otolaryngologist and objective phoniatric methods in the evaluation of MG and other myasthenia-like neurological diseases. The use of these methods for the assessment of phoniatric symptoms in neurological diseases is highly recommended.
Tóth
L
L
HNO-Klinik, Universität Debrecen, Ungarn. LTOTH@jaguar.dote.hu
Pap
U
U
Diószeghy
P
P
Sziklai
I
I
D000328:Adult; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D009157:Myasthenia Gravis / Q000175:diagnosis* / Q000188:drug therapy; D010348:Patient Care Team; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D013018:Sound Spectrography; D014832:Voice Disorders / Q000175:diagnosis* / Q000188:drug therapy; D014833:Voice Quality / Q000187:drug effects
D002800:Cholinesterase Inhibitors; D011729:Pyridostigmine Bromide
Phoniatrische Untersuchungen an Patienten mit Myasthenia gravis.